

Graphite Bio, a next-generation gene editing company, has secured $45 million in Series A financing. Versant Ventures led the round with participation from Samsara BioCapital.
Source: Press Release
Graphite Bio, a next-generation gene editing company, has secured $45 million in Series A financing.
Graphite Bio, a next-generation gene editing company, has secured $45 million in Series A financing. Versant Ventures led the round with participation from Samsara BioCapital.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination